The new indication for empagliflozin is to reduce risk of CV death and hospitalization for heart failure in patients with HFrEF,
Low-income patients with diabetes enrolled in high-deductible health plans used less preventive and primary care services and more emergency visits, suggests new review.
Take this quick quiz to test your knowledge of key findings in recent studies on the cardioprotective effects of SGLT2i and GLP-1 RAs.
These concise summaries highlight the latest findings on the cardioprotective effects of SGLT2 inhibitors and GLP-1 RA in patients with diabetes.
Five years after bariatric surgery for uncontrolled T2D patients reported improvements in physical health and QoL but measures of psychosocial wellbeing remained flat.
Antidepressant therapy, used as prescribed, reduced risk for advanced complications of diabetes and death among more than 36 000 patients with comorbid diabetes and depression.
Early attainment of an A1c level below 7% was predictive of long-term glycemic control in patients with type 2 diabetes starting second-line glucose-lowering therapy in a new analysis.
The first nonsteroidal mineralocorticoid receptor antagonist to be approved for adults with T2D-associated CKD fills a significant treatment void for millions of patients.
A recent study found that the use of statins in patients with newly diagnosed T2D reduced incidence of cardiovascular disease and death, particularly among older patients.
The SGLT-2 inhibitor class, originally approved as antihyperglycemic agents for T2D, has proven "pluripotent," adding indications for related conditions. Test your knowledge of a few basic facts.